Mirtazapina Cinfa (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Cinfa, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and works by modulating central neurotransmitter activity.

GNH USA supplies Mirtazapina Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a tetracyclic antidepressant used primarily in the management of depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves mood. - Depressive episodes with insomnia: enhances sleep quality and reduces nighttime awakenings. - Depressive episodes with anxiety: alleviates associated anxiety and tension.

Mirtazapine may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Sedation or drowsiness: feeling unusually sleepy, especially at treatment initiation. - Increased appetite and weight gain: noticeable rise in hunger and body weight. - Dry mouth: reduced salivation causing oral dryness. - Constipation: infrequent or difficult bowel movements. - Dizziness: sensation of light‑headedness or imbalance.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, increasing infection risk. - Seizures: occurrence of convulsive episodes. - Hepatotoxicity: liver enzyme elevations or liver injury. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Severe allergic reactions: rash, swelling, or difficulty breathing.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: excreted in milk; consider alternative therapy. - Elderly patients: start at low dose due to heightened sensitivity to sedation. - Hepatic impairment: dose adjustment may be required. - Concomitant CNS depressants: increase risk of excessive sedation. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis; discontinue MAOI at least 14 days prior. - CNS depressants (e.g., benzodiazepines, alcohol): may cause profound sedation or respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Anticholinergic agents: additive dry mouth and constipation. - Warfarin: potential alteration of INR; monitor coagulation parameters. - Lithium: possible increase in lithium levels; monitor serum lithium.